Nektar enters quiet period ahead of Phase 2b REZOLVE-AA follow-up data

NEKTAR THERAPEUTICS

Quiet period begins September 8, 2026 until 24-week off-treatment follow-up data from Phase 2b REZOLVE-AA study is announced.
Study evaluates rezpegaldesleukin in patients with severe-to-very-severe alopecia areata.
Quiet period is consistent with prior quiet periods for Phase 2b REZOLVE studies and planned data disclosures.
No financial or operational results disclosed in this filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.